CliniMARK COST Action Final Meeting

Monday, 15 March 2021 09:00 - 13:30


09:00h - 09:15h Welcome.

Fernando J. Corrales, National Center of Biotechnology.

Eva M. Martínez Cáceres, Autonomous University of Barcelona.

Mª José Torres Jaén, Malaga University, Malaga Regional University Hospital, Spain.

Begoña Oliver Martos, Institute of Biomedical Research of Malaga (IBIMA).


09:15h - 09:45h Biomarkers and health. Proteomics-based biomarker discovery and translation in rheumatic disorders.

Francisco J. Blanco, Institute of Biomedical Research A Coruña.


09:45h - 10:15h Working Group 1. Selection and analytical validation of biomarker detection techniques.

Exosomes: Novel Biomarkers for Clinical Diagnosis.

Samar Marei, Head of MSc Programm in Biotechnology.

Ephraim Katzir, Department of Biotechnology Engineering, ORT Braude College.


10:15h - 10:45h Working Group 2. Biomarker clinical feasibility study design.

Where do we stand with the manuscript for WP2 and how do we continue with whom still?

Peter Groenen, Head of Translational Biomarkers, Idorsia Pharmaceuticals Ltd..


10:45h - 11:00h Break


11:00h – 11:30 h Working Group 3. Implementation of best biomarker practice guidelines: demonstrator project COPD.

Part I – About WG3. Achievements / Perspectives

Part II – Short invited presentations.

Deborah Penque, National Health Institute Doutor Ricardo Jorge.


11:30h - 12:00h Working Group 4. Capacity building.

Summary of dissemination of biomarker research output and discussion on sustainability.

Daniela Krasser, Quality Management Officer, BBMRI-ERIC.


12:00h - 12:30h Education activities: STSM and Training School.

Makis Zoidakis, Biomedical Research Foundation, Academy of Athens (BRFAA).


12:30h - 13:00h Concluding remarks.

Theo M. Luider, Dept. of Neurology, Erasmus MC, the Netherlands.

Antonia Vlahou, Biomedical Research Foundation Academy of Athens.


Further information: see Attachment: Download.